Facebook Page Cannot Leave Out Risk Information, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of Prescription Drug Promotion also expresses concern that Facebook page for hypothyroidism drug Tirosint fails to include limits on the indication.
You may also be interested in...
Warning For Facebook “Likes” Reflects FDA Social Media Approach
FDA is revealing its views on social media use through individual enforcement actions and provisions in disparate guidances, in the absence of issuing an overarching guidance. A recent warning letter sheds light on the agency’s view of “liking” something on Facebook.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.